Kanav Saraf, PhD, represents Sensydia (www.sensydia.com), a medtech company recognized with an NIH grant and FDA Breakthrough Device designation for its innovative, non-invasive technology. Sensydia's Cardiac Performance System (CPS) provides insights to help clinicians manage heart and lung conditions, aiming to improve patient outcomes and reduce the need for invasive procedures.